Jazz Pharmaceuticals plc — Director's Dealing 2020

Nov 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2020-11-02

Reporting Person: BERNS PAUL L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-02	Ordinary Shares	M	4691	—	Acquired	14431	Direct
2020-11-04	Ordinary Shares	S	466	$147.44	Disposed	13965	Direct
2020-11-04	Ordinary Shares	S	400	$149.2775	Disposed	13565	Direct
2020-11-04	Ordinary Shares	S	3825	$150.8982	Disposed	9740	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-02	Phantom Stock	$	M	4691	Disposed	2020-11-02	Ordinary Shares (4691)	Direct

Footnotes

F1: On November 2, 2020, the Reporting Person's 4,691 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares.

F2: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $149.04 to $149.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $150.515 to $151.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.